Revenue for the second quarter of 2009 was $136,000, compared to $96,000 for the second quarter of 2008. The increase of approximately $40,000 in revenue from the second quarter of 2008 compared to the second quarter of 2009 was due to an increase in Altrazeal(TM) product sales of $47,000 and $15,000 in sponsored research as the prior year included a non-recurring revenue adjustment. These revenue increases were partially offset by a decrease of $10,000 in Zindaclin(R) royalties.
Research and development expenses for the second quarter of 2009 were $854,000, including $213,000 in share-based compensation, compared to $888,000, including $40,000 in share-based compensation, for the second quarter of 2008. The decrease of approximately $33,000 in research and development expenses was primarily due to lower product development costs of $265,000 associated with our Altrazeal(TM) and OraDisc(TM) technologies. This decrease was partially offset by an increase of $96,000 in regulatory expenses for consultants engaged for our regulatory filings for Altrazeal(TM) related products, increased clinical testing expenses of $21,000 for Altrazeal(TM) and Altrazeal(TM) Silver, and additional compensation costs of approximately $125,000, primarily for the vesting of certain restricted stock awards associated with the Company's workforce reduction in June 2009.
Selling, general and administrative expenses for the second quarter of 2009 were $1.8 million, including $279,000 in share-based compensation, compared to $1.3 million, including $220,000 in share-based compensation, for the second quarter of 2008. The increase of approximately $0.5 million in selling, general and administrative expen
|SOURCE ULURU Inc.|
Copyright©2009 PR Newswire.
All rights reserved